| Literature DB >> 30455867 |
Cho-Han Chiang1, Sung-Ching Pan2, Tyan-Shin Yang1, Keisuke Matsuda3, Hong Bin Kim4,5, Young Hwa Choi6, Satoshi Hori7, Jann-Tay Wang1,2,8, Wang-Huei Sheng1,2,8, Yee-Chun Chen1,2,8,9, Feng-Yee Chang10, Shan-Chwen Chang1,2.
Abstract
Background: Sustainable systematic interventions are important for infection prevention and control (IPC). Data from surveillance of healthcare-associated infections (HAI) provides feedback for implementation of IPC programs. To address the paucity of such data in Asia, we searched for national HAI surveillance and IPC programs in this region.Entities:
Keywords: Antimicrobial resistance; Healthcare-associated infections; Infection prevention and control program; National policy; National surveillance
Mesh:
Year: 2018 PMID: 30455867 PMCID: PMC6223041 DOI: 10.1186/s13756-018-0422-1
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Demographics and national surveillance systems of Taiwan, South Korea and Japan
| Parameter | Taiwan | South Korea | Japan |
|---|---|---|---|
| Country background | |||
| Populationa | 23,433,753b | 50,746,659c | 127,276,000d |
| Income brackete | High income | High income | High income |
| GDP, US dollars | 571,736 millionf | 1,530,750.92 milliong | 4,872,136.95 milliong |
| Share of GDP on national health expenditure | 6.3%f | 7.6%h | 10.7%h |
| Number of hospitalsa | 486i | 534j | 7426k |
| Surveillance system | Taiwan Nosocomial Infection Surveillance (TNIS) | Korean National Healthcare-associated Infection Surveillance System (KONIS) | Japan Nosocomial Infection Surveillance (JANIS) |
| Year established | 2001 | 2006 | 2000 |
| Authority | Centers for Disease Control, Ministry of Health and Welfare, Taiwan | Korea Centers for Disease Control and Prevention | Ministry of Health, Labor and Welfare, Japan |
| ICU Surveillancea | |||
| Number of hospitals enrolled | 103 | 96 | 143 |
| Number of ICUs enrolled | 472 | 169 | 163 |
| Types of hospitals enrolled (total number in the country) | Medical Centers and Regional hospitals l ( | Bed size > 900, 700–899, 300–699 ( | Bed size > 200 ( |
| Hospital coverage rate | 21.2% (103/486) | 18.0% (96/534) | 1.9% (143/7426) |
| Hospital participation ratem | 100.0% (103/103) | 38.6% (96/249) | 6.8% (143/2100) |
| Mandated standard ratio of infection control personnel | 1 dedicated full-time certificated IC nurse per 300 beds (basic) or per 250 beds (optimal) | 1 dedicated full-time IC nurse per 200 beds (basic) or per 150 beds (optimal)n | 1 dedicated full-time certificated IC nurse (at > 0.8 FTE)p |
| Healthcare-associated infection data provided | |||
| Site-specific HAIs | UTI, BSI, HAP: episode per 1000 patient-day | UTI, BSI, HAP: episode per 1000 patient-day | UTI: episode per 1000 patient-day |
| Device-associated HAIs | CAUTI, CLABSI, VAP: episode per 1000 device-day | CAUTI, CLABSI, VAP: episode per 1000 device-day | CLABSI, VAP: episode per 1000 patient-day |
| Causative pathogens | Top 10 of the most common pathogens | 99% of all the causative pathogens | Top 5 of the most common pathogensq |
| Antimicrobial-resistant pathogens | MRSA, VRE, CRAB, CRPA, CRE, CREC, CRKP | MRSA, VRE, IRAB, IRPA, CefR-KP, CipR-KP, CefR-EC, CipR-EC | MRSA |
Abbreviations: BSI bloodstream infections, CAUTI catheter-associated urinary tract infection, CefR-EC cefotaxime-resistant Escherichia coli, CefR-KP cefotaxime-resistant Klebsiella pneumoniae, CipR-EC ciprofloxacin-resistant E. coli, CipR-KP ciprofloxacin-resistant K. pneumoniae, CLABSI central line-associated bloodstream infections, CRAB carbapanem (imipenem or meropenem)-resistant Acinetobacter baumannii, CRE carbapanem (imipenem, meropenem, or ertapenem)-resistant Enterobacteriaceae, CREC carbapanem (imipenem, meropenem, or ertapenem)-resistant E. coli, CRKP carbapanem (imipenem, meropenem, or ertapenem)-resistant K. pneumoniae, CRPA carbapanem (imipenem or meropenem)-resistant Pseudomonas aeruginosa, FTE full-time equivalent, GDP gross domestic product, HAI Healthcare-associated infections, HAP hospital-acquired pneumonia, IC infection control, IRAB imipenem-resistant A. baumannii, IRPA imipenem-resistant P. aerugonisa, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible S. aureus, UTI urinary tract infections, VAP ventilator-associated pneumonia, VRE vancomycin-resistant enterococci (Enterococcus faecalis or E. faecium)
a2014 data
bData retrieved from http://www1.stat.gov.tw/ct.asp?xItem=15408&CtNode=4692&mp=3. Assessed 14 April 2018.
cData retrieved from https://data.worldbank.org/country/korea-rep. Assessed 14 April 2018
dData retrieved from https://data.worldbank.org/country/japan?view=chart. Assessed 14 April 2018
eData retrieved from World Bank Country and Lending Groups at https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed 10 September 2018. For the current 2019 fiscal year, high-income economies are those with a gross national income per capita, calculated using the World Bank Atlas method of $12,056 or more
f2016 data. Raw data NT dollars 17,152,093 million, converted to US dollars by ratio 30:1. Retrieved from https://www.mohw.gov.tw/lp-3781-2.html. Accessed 10 September 2018
g2017 data based on World Bank national accounts data, and Organization for Economic Co-operation and Development (OECD) National Accounts data. Retrieved from https://data.worldbank.org/indicator/NY.GDP.MKTP.CD. Accessed 10 September 2018
h2017 data based on Organization for Economic Co-operation and Development (OECD) estimated data for Japan and provisional data for Korea. Retrieved from https://stats.oecd.org/Index.aspx?DataSetCode=SHA. Accessed 10 September 2018
iData retrieved from https://www.mohw.gov.tw/dl-40542-045687b7-aa43-458c-ab70-e8ff24c5b1b3.html. Accessed 10 September 2018
jData retrieved from http://kosis.kr/eng/statisticsList/statisticsList_01List.jsp?vwcd=MT_ETITLE&parentId=D#SubCont. Accessed 10 September 2018
kData retrieved from http://www.mhlw.go.jp/english/database/db-hh/2-2.html. Accessed 10 September 2018
lThe data for Taiwan included medical centers and regional hospitals, which were classified according to hospital accreditation and covered only acute care hospitals
mThe hospital coverage rate was calculated as the number of participating hospitals divided by the total number of hospitals in the same year in each country. The hospital participation rate was calculated as the number of participating hospitals divided by the total number of hospitals to be enrolled in each surveillance system
nIn terms of surveillance, the requirement for participation in KONIS was 1 full-time infection control nurse over 200-bed size hospital. Regarding the mandatory personnel requirement, this regulation has been launched as a financial incentive program since 2016, as described in Additional file 2: Table S2
oData available at https://www.cdc.gov.tw/professional/info.aspx?treeid=beac9c103df952c4&nowtreeid=bd387fa55fef03f0&tid=FED32554F2B55D11. Accessed September 10, 2018
pInfection prevention and control incentive through reimbursement policies was revised in 2010, 2012 and 2018, as described in Additional file 2: Table S2. Since 2012, each hospital is reimbursed 1000 JPY (about 10 USD) per patient per admission if it fulfills the Ministry of Health, Labor and Welfare requirements which mandated one dedicated full-time certificated ICN (at > 0.8 FTE), one part-time ICD (at > 0.5 FTE), one part-time IC pharmacist and one part-time medical technician/microbiologist (at > 0.5 FTE). Since 2018, reimbursement policies per admission included three parts. It provides 3900 JPY (about 39 USD) per admission for infection prevention and control incentive at a major hospital, or 1000 JPY for a small hospital. Additional 1000 JPY was reimbursed if this hospital participates a local IPC network incentive. Another 1000 JPY was reimbursed for AS incentive. For hospitals with AS incentive, it mandates the following manpower in addition to 2012 requirements: one part-time doctor mainly for AS (at > 0.5 FTE), one full-time ICP either a certificated ICN or IC pharmacist or medical technician
qMRSA and MSSA are listed as separate pathogens
Fig. 1Incidence densities of healthcare-associated infections in intensive care units across Taiwan, South Korea, and Japan from 2008 to 2015. Abbreviations: AMR: antimicrobial-resistance; HAI: healthcare-associated infections; ICN: infection control nurse; ICP: infection control personnel; IPC: infection prevention and control; JANIS: Japan Nosocomial Infection Surveillance; ICD: infection control doctor; KONIS: Korean National Healthcare-associated Infection Surveillance; MDRO: multi-drug resistant organisms; TNIS: Taiwan Nosocomial Infection Surveillance. a In 1984, every teaching hospital in Taiwan was required to have one ICN per 300 hospital beds. In 2004, hospitals with more than 500 beds are required to have at least one ICD, and hospitals with more than 300 beds are required to have at least one ICN per 250 beds. In 2017, hospitals with more than 500 beds are encouraged to have one ICD for every 300 beds and one ICN for every 250 beds (Table 1). b Included training healthcare staff, establishing infection control committees, and formulating hospital policies. c Restricts use of antimicrobials in ambulatory patients with upper respiratory infections but without evidence of bacterial infection. d Act 29 specifies that IPC are the duties of hospitals with more than 300 beds. Act 47 mandates IPC as part of hospital accreditation. In 2012, hospitals with more than 200 beds are required to appoint an infection control committee and at least one full-time experienced staff (Table 1). e Japanese medical law obligated all health care institutions to implement operational safety measures against HAI, which includes IPC guidelines, IPC training, and disease reporting. f Hospitals should have an infection control team that consists of ICN, ICD, infection control pharmacist and infection control microbiology technologist. Hospitals should also have an IPC policy and antimicrobial stewardship program (Table 1). a Taiwan; b South Korea; c Japan
Fig. 2Annual trends of device-associated infections in intensive care units from 2008 to 2015. Data are presented as episodes per 1000 device-days (Taiwan, Korea) or episodes per 1000 patient-days (Japan; data comprised urinary tract infections, central line-associated bloodstream infections and ventilator-associated pneumonia). a Catheter-associated urinary tract infections; b Central line-associated bloodstream infections; c Ventilator-associated pneumonia
Common causative pathogens of healthcare-associated infections in intensive care units enrolled in the national surveillance systems of Taiwan, South Korea, and Japan in 2015
| Rank | Organism | Proportion | Organism | Proportion | Organism | Proportion |
|---|---|---|---|---|---|---|
| Urinary Tract Infectionsa | Taiwan ( | South Korea ( | Japan ( | |||
| 1 |
| 19.8% |
| 17.6% |
| 37.6% |
| 2 |
| 16.9% |
| 12.6% |
| 16.3% |
| 3 |
| 8.5% |
| 9.5% |
| 7.9% |
| 4 |
| 7.4% |
| 9.3% |
| 6.9% |
| 5 |
| 7.3% |
| 8.6% |
| 6.4% |
| Bloodstream Infections | Taiwan ( | South Korea ( | Japanb ( | |||
| 1 |
| 10.4% |
| 14.7% |
| 15.7% |
| 2 |
| 9.6% |
| 14.2% |
| 13.0% |
| 3 |
| 7.2% |
| 12.6% | Coagulase negative staphylococci | 10.1% |
| 4 |
| 6.5% | Coagulase negative staphylococci | 12.0% |
| 5.6% |
| 5 |
| 6.2% |
| 7.3% | ||
| Pneumonia | Taiwan ( | South Korea ( | Japanc ( | |||
| 1 |
| 22.5% |
| 34.5% |
| 21.8% |
| 2 |
| 18.0% |
| 28.5% |
| 18.6% |
| 3 |
| 16.2% |
| 9.4% |
| 7.8% |
| 4 |
| 9.0% |
| 8.8% |
| 6.8% |
| 5 |
| 6.2% |
| 3.2% | ||
aThe National Healthcare Safety Network definition of catheter-associated urinary tract infections was updated in 2015, and excluded Candida, yeasts or molds as potential pathogens. Nevertheless, TNIS, KONIS and JANIS kept these pathogens and data are provided
bJapan’s data on bloodstream infection represents central line-associated bloodstream infections
cJapan’s data on pneumonia represents ventilator-associated pneumonia
Fig. 3Trends of the numbers and the proportions of antimicrobial resistance in selected bacteria causing healthcare-associated infections in the intensive care units in Taiwan and South Korea. Note: The proportions of antimicrobial resistance in selected pathogens were calculated as numbers of antimicrobial-resistant isolates divided by the total numbers of isolates of the same species. Japan’s data included non-ICU patients and were not shown. a Methicillin-resistant Staphylococcus aureus; b Carbapenem-resistant Pseudomonas aeruginosa; c Carbapenem-resistant Acinetobacter baumannii
Comparison of healthcare-associated infections in intensive care units across different geographic regions
| Site-specific HAI | Device-associated HAI | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Countries/Regions (surveillance system) | Data source or type of study | Year | Overalla | UTI b | BSI | HAP | CAUTIb | CLABSI | VAP |
| Taiwan (TNIS) | National surveillance | 2015 | 5.0 (8514/1692998) | 2.1 | 2.1 | 0.8 | 3.0 | 3.7 | 1.1 |
| South Korea (KONIS) | National surveillance | 2015 | 2.8c (2608/945605) | 0.8 | 1.3 | 0.7 | 0.9 | 2.2 | 1.0 |
| Japan (JANIS) | National surveillance | 2015 | 2.7d (952/347386) | 0.5 | – | – | – | 0.7e | 1.5e |
| USA (NHSN) [ | National surveillance | 2012 | 1.6f (37872/23344616) | – | – | – | 2.1 | 1.1 | 1.4 |
| Europe (HAI-net) [ | National surveillance | 2015 | 2.6 (15821/6177114) | 1.1 | 2.0 | 4.0 | 3.6 | 3.6 | 10.0 |
| Southeast Asia [ | Meta-analysisg | 2000–2012 | 20.0h (16.9450/26681) | – | – | – | 8.9 | 4.7 | 14.7 |
| Developing countries worldwide [ | Meta-analysisg | 1995–2008 | 47.9h (28.54250/148893) | – | – | – | 9.8 | 11.3 | 22.9 |
| Developing countries worldwide (INICC)i [ | Multi-center study | 2010–2015 | – | – | – | – | 5.1 | 4.1 | 13.1 |
Abbreviations: BSI bloodstream infections, CAUTI catheter-associated urinary tract infections, CLABSI central line-associated bloodstream infections, HAI healthcare-associated infections, HAI-net Healthcare-associated Infections Surveillance Network (Europe), HAP hospital-acquired pneumonia, ICU intensive care units, INICC International Nosocomial Infection Control Consortium (developing countries worldwide), NHSN National Healthcare Safety network (USA), UTI urinary tract infections, VAP ventilator-associated pneumonia
aData are pooled mean of site-specific HAI such as UTI, BSI, and HAP or otherwise specified, and computed from raw data provided in the reports. Thus, all these data should be interpreted appropriately
bThe NHSN CAUTI definition was updated in 2015 and excluded Candida, yeasts or molds as potential CAUTI pathogens. Nevertheless, TNIS, KONIS and JANIS kept these pathogens and data are provided
cData were collected during July 2015–June 2016
dData are pooled means of UTI, CLABSI and VAP
eData were calculated by episodes/1000 patient-day
fData are pooled means of CAUTI, CLABSI and VAP
gInfection frequencies reported in high-quality studies were greater than those from low-quality studies
hWeights were given to different studies to compute the final data. Unweighted raw data were derived from the original article and denoted in parenthesis
iData were prospectively collected from 861,284 patients in 703 ICUs from 50 countries